你即將離開本站

並前往https://www.annalsofoncology.org/article/S0923-7534(19)59736-8/fulltext

Phase II study of osimertinib in NSCLC patients with EGFR ...

EGFR exon 20 insertion mutations account for up to 4% of all EGFR mutations and are generally resistant to EGFR TKIs. Although osimertinib is ...

確定！ 回上一頁

查詢 「Insertion mutation」的人也找了：

  1. insertion mutation中文
    2.
  2. Inversion mutation
    3.
  3. Structural mutation
    4.
  4. Gene mutation
    5.
  5. DNA mutation
    6.
  6. Nonsense mutation
    7.
  7. Insertion mutation
    8.
  8. Silent mutation
    9.